Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH-Reference-Cited by-同舟云学术

Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH

Published:2016-08 Issue:8 Volume:14 Page:1668-1672
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Iorio A.¹²^ORCID,Barbara A. M.²^ORCID,Bernardi F.³,Lillicrap D.⁴,Makris M.⁵,Peyvandi F.⁶⁷,Rosendaal F.⁸,

Affiliation:

1. Department of Medicine; McMaster University; Hamilton ON Canada

2. Department of Clinical Epidemiology and Biostatistics; McMaster University; Hamilton ON Canada

3. Department of Biochemistry and Molecular Biology; University of Ferrara; Ferrara Italy

4. Pathology; Queens University; Kingston, ON Canada

5. Sheffield Haemophilia and Thrombosis Centre; Royal Hallamshire Hospital; Sheffield UK

6. A. Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy

7. Department of Pathophysiology and Transplantation Università degli Studi di Milano; Milan Italy

8. Einthoven Laboratory for Experimental Vascular Medicine; Leiden University Medical Center; Leiden the Netherlands

Funder

Alexion Pharmaceuticals

Novo Nordisk

Biotest

Grifols

Kedrion

LFB

Bayer

Ablynx

CSL Behring

SOBI

Octapharma

Baxalta

Biogen

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13382/fullpdf

Reference29 articles.

1. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom;Hay;Blood,2011

2. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization;Colvin;Br J Haematol,1995

3. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99;Darby;J Thromb Haemost,2004

4. Impact of inhibitors on hemophilia a mortality in the United States;Walsh;Am J Hematol,2015

5. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database;Carpenter;Haemophilia,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha;Haemophilia;2018-08-08

2. Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy;Therapeutic Advances in Hematology;2018-07-30

3. Factor VIIIproducts and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review;Journal of Thrombosis and Haemostasis;2018-05-24

4. A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII;Haemophilia;2018-02-01

5. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study;Journal of Korean Medical Science;2018